Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota Identifier:
First received: November 12, 2009
Last updated: June 11, 2013
Last verified: June 2013

November 12, 2009
June 11, 2013
December 2009
February 2013   (final data collection date for primary outcome measure)
To determine the optimal tolerated regimen (OTR) of pazopanib and ixabepilone when used in combination by evaluation of toxicity and tolerability [ Time Frame: At first cycle (Week 3) ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01012362 on Archive Site
To obtain preliminary toxicity and tolerability of this drug regimen. [ Time Frame: Up to 30 days post treatment ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.

Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily. Disease assessment will be done every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable toxicity or patient refusal.

Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Breast Cancer
  • Lung Cancer
  • Colon Cancer
  • Pancreatic Cancer
  • Head and Neck Cancer
  • Kidney Cancer
  • Sarcoma
  • Hepatocellular Cancer
  • Drug: Pazopanib
    Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
    Other Names:
    • Pazopanib hydrochloride
    • GW786034B
  • Drug: Ixabepilone
    Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
    Other Name: IXEMPRA(TM)
Experimental: Pazopanib and Ixabepilone

Patient receives assigned dose level:

Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 25 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.

  • Drug: Pazopanib
  • Drug: Ixabepilone
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of advanced non-hematologic solid tumor malignancy, including, but not limited to breast, lung, colon, pancreatic, head and neck, kidney or sarcoma that has failed or become intolerant to standard therapy and is no longer likely to respond to such therapy Effective with the August 2011 version of the protocol, enrollment is limited to squamous cell carcinoma of the head and neck (refer to section 1.4 for rationale). Note: Patients with a primary diagnosis of hepatocellular carcinoma will be eligible for enrollment into dose level 1 or 2 only, provided they met all other inclusion/exclusion criteria - the maximum tolerated dose (MTD) for pazopanib monotherapy in patients with hepatocellular cancer was found to be 600 mg daily.
  • Measureable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST).
  • Prior systemic chemotherapy, immunotherapy, or biological therapy is allowed; however prior use of either pazopanib or ixabepilone alone or in combination is not allowed.
  • At least 14 days must have elapsed since 1) previous systemic therapy (28 days for bevacizumab) before the 1st dose of study drug, 2) last dose of radiation therapy or surgery (28 days for major surgery).
  • Patient must have recovered from the acute toxic effects of previous anti-cancer treatment prior to study enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Adequate organ function within 14 days of enrollment defined as:

    • Absolute neutrophil count (ANC) >1.5 x 10^9/L
    • Hemoglobin > or = 9 g/dL
    • Platelets > or = 100 x 10^9/L
    • Prothrombin time or international normalized ratio, and partial thromboplastin time (PTT) < or = 1.2 x upper limit of normal (ULN)
    • Total bilirubin < or = ULN
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < or = 2.5 x ULN
    • Serum creatinine < or = 1.5 mg/dL
    • Urine protein to Creatinine Ratio < 1
    • Total serum calcium < 12.0 mg/dL
  • Men and women with child-bearing potential must adhere to protocol criteria to prevent conception during study

Exclusion Criteria:

  • Women who are pregnant or nursing.
  • Prior radiation to > =or = 30% of major bone marrow containing areas (pelvis, lumbar spine)
  • History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis
  • Clinically significant gastrointestinal abnormalities that may increase the risk of GI bleeding or may affect absorption of investigational product
  • History of another malignancy - must be at least 3 years disease-free
  • Presence of uncontrolled infection
  • Prolongation of corrected QT interval (QTc) > 480 msecs
  • History of any one or more of the following cardiovascular conditions within the past 6 months:

    • Cardiac angioplasty or stenting
    • Myocardial infarction
    • Unstable angina
    • Coronary artery bypass graft surgery
    • Symptomatic peripheral vascular disease
    • Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)
  • Poorly controlled hypertension
  • History of cerebrovascular accident,pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
  • Prior major surgery or trauma within 28 days prior to 1st dose of study drug
  • Evidence of active bleeding or bleeding diathesis
  • Known endobronchial lesions or involvement of large pulmonary vessels by tumor
  • Hemoptysis with 6 weeks of 1st dose of study drug
  • Neuropathy Grade 1
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
2009LS001, 0906M68402, NCI-2009-01444
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Principal Investigator: Arkaduisz Z Dudek, MD Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP